KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Tax Provisions (2017 - 2025)

Acadia Pharmaceuticals has reported Tax Provisions over the past 9 years, most recently at $3.1 million for Q4 2025.

  • Quarterly results put Tax Provisions at $3.1 million for Q4 2025, down 82.25% from a year ago — trailing twelve months through Dec 2025 was -$1.8 million (down 105.59% YoY), and the annual figure for FY2025 was -$1.8 million, down 105.6%.
  • Tax Provisions for Q4 2025 was $3.1 million at Acadia Pharmaceuticals, up from -$27.2 million in the prior quarter.
  • Over the last five years, Tax Provisions for ACAD hit a ceiling of $17.3 million in Q4 2024 and a floor of -$27.2 million in Q3 2025.
  • Median Tax Provisions over the past 5 years was $817500.0 (2022), compared with a mean of $2.1 million.
  • Biggest five-year swings in Tax Provisions: soared 2209.52% in 2022 and later tumbled 824.55% in 2023.
  • Acadia Pharmaceuticals' Tax Provisions stood at $189000.0 in 2021, then skyrocketed by 341.8% to $835000.0 in 2022, then tumbled by 824.55% to -$6.0 million in 2023, then soared by 386.35% to $17.3 million in 2024, then plummeted by 82.25% to $3.1 million in 2025.
  • The last three reported values for Tax Provisions were $3.1 million (Q4 2025), -$27.2 million (Q3 2025), and $13.5 million (Q2 2025) per Business Quant data.